Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally.
No risks detected for ATRI from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$713.49|
|52 Week High||US$567.00|
|52 Week Low||US$783.84|
|1 Month Change||4.90%|
|3 Month Change||14.12%|
|1 Year Change||13.04%|
|3 Year Change||4.45%|
|5 Year Change||63.42%|
|Change since IPO||9,520.09%|
Recent News & Updates
|ATRI||US Medical Equipment||US Market|
Return vs Industry: ATRI underperformed the US Medical Equipment industry which returned 23.1% over the past year.
Return vs Market: ATRI underperformed the US Market which returned 30.3% over the past year.
Stable Share Price: ATRI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ATRI's weekly volatility (3%) has been stable over the past year.
About the Company
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company’s cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery.
Atrion Fundamentals Summary
|ATRI fundamental statistics|
Is ATRI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATRI income statement (TTM)|
|Cost of Revenue||US$84.86m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||17.36|
|Net Profit Margin||21.14%|
How did ATRI perform over the long term?See historical performance and comparison
1.1%Current Dividend Yield
Is Atrion undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ATRI ($711.8) is trading above our estimate of fair value ($201.96)
Significantly Below Fair Value: ATRI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ATRI is good value based on its PE Ratio (41x) compared to the US Medical Equipment industry average (49.9x).
PE vs Market: ATRI is poor value based on its PE Ratio (41x) compared to the US market (18.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRI is overvalued based on its PB Ratio (5.3x) compared to the US Medical Equipment industry average (4.3x).
How is Atrion forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Atrion has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Atrion performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRI has high quality earnings.
Growing Profit Margin: ATRI's current net profit margins (21.1%) are lower than last year (22.7%).
Past Earnings Growth Analysis
Earnings Trend: ATRI's earnings have grown by 2.2% per year over the past 5 years.
Accelerating Growth: ATRI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ATRI had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (36.1%).
Return on Equity
High ROE: ATRI's Return on Equity (13%) is considered low.
How is Atrion's financial position?
Financial Position Analysis
Short Term Liabilities: ATRI's short term assets ($125.8M) exceed its short term liabilities ($12.7M).
Long Term Liabilities: ATRI's short term assets ($125.8M) exceed its long term liabilities ($14.2M).
Debt to Equity History and Analysis
Debt Level: ATRI is debt free.
Reducing Debt: ATRI has not had any debt for past 5 years.
Debt Coverage: ATRI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ATRI has no debt, therefore coverage of interest payments is not a concern.
What is Atrion current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ATRI's dividend (1.1%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.28%).
High Dividend: ATRI's dividend (1.1%) is low compared to the top 25% of dividend payers in the US market (3.48%).
Stability and Growth of Payments
Stable Dividend: ATRI's dividends per share have been stable in the past 10 years.
Growing Dividend: ATRI's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40.9%), ATRI's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
David Battat (51 yo)
Mr. David A. Battat has been the Chief Executive Officer of ATRION Corp. since May 26, 2011 and has been its President since May 2011. Mr. Battat has been the President of Halkey-Roberts Corporation, a sub...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD2.07M) is below average for companies of similar size in the US market ($USD3.49M).
Compensation vs Earnings: David's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Board: ATRI's board of directors are seasoned and experienced ( 23.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Atrion Corporation's employee growth, exchange listings and data sources
- Name: Atrion Corporation
- Ticker: ATRI
- Exchange: NasdaqGS
- Founded: 1944
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$1.285b
- Shares outstanding: 1.80m
- Website: https://www.atrioncorp.com
Number of Employees
- Atrion Corporation
- One Allentown Parkway
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 22:31|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.